ImmunoGen, Inc. develops targeted anticancer therapeutics using our expertise in cancer biology, engineered antibodies and highly potent cancer-cell killing agents.
We have established expertise in the development and humanization of tumor-targeting antibodies. As is well accepted, engineered antibodies can do an excellent job of selectively binding to cancer cells, but are typically sub-optimal in their ability to actually kill cancer cells. Thus, we have developed specialized cancer-cell killing agents to serve as payloads – to be attached to such antibodies for targeted delivery to tumor cells.
Our payload agents are many fold more potent than traditional chemotherapy agents. We also have developed engineered linkers that keep the payload firmly attached to the antibody while the whole therapy is circulating through the bloodstream and then release it once the therapy has reached and entered a cancer cell.
We use our antibody-drug conjugate (ADC) technology – together with our strong antibody expertise – to develop our own product candidates. We currently have three wholly owned clinical-stage compounds – IMGN853, IMGN529 and IMGN289. We continue to invest in our ADC technology to maintain our leadership position.
We also selectively outlicense our technology to other companies for use with their engineered antibodies. We have partnerships with Amgen, Bayer, Biotest, Lilly, Novartis, Roche and Sanofi – all of which have clinical and/or preclinical compounds utilizing our technology.
ImmunoGen is headquartered in Waltham, Massachusetts. Our manufacturing facility is in Norwood, Massachusetts. We have approximately 300 employees.
Last updated January 31, 2014